Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma

This study is examining whether two investigational drugs (DFMO and AMXT 1501) that block a specific cell-growth pathway (polyamine synthesis) can alter the metabolism inside brain tumors. Patients receiving these drugs before brain tumor surgery allow researchers to measure changes inside the tumor using a special monitoring technique during recovery. **You may be eligible if...** - You are 18 or older with a suspected or confirmed high-grade brain tumor (diffuse glioma), based on clinical and imaging findings - You are scheduled for a biopsy or partial removal of the tumor at Mayo Clinic (Rochester, MN) - You are willing to stay in the hospital for up to 3 extra days after surgery for monitoring - Your blood counts and organ function are within acceptable ranges **You may NOT be eligible if...** - You are not a suitable candidate for surgery due to medical history or current illnesses - You are pregnant or breastfeeding - You have another serious medical condition that would interfere with the study Talk to your doctor to see if this trial is right for you.